EANM 2025: 225Ac-SSO110 Data Supports the Advancement for ES-SCLC and MCC
“These oral presentations demonstrate Ariceum’s commitment to leading innovation in targeted radiotherapeutics,” said Germo Gericke, MD, Chief Medical Officer of Ariceum Therapeutics. “For the first time, we are presenting data showing minimal in-vivo redistribution of daughter radionuclides with 225Ac-SSO110, a non-internalizing SSTR2 antagonist, an important advance in our understanding of targeted alpha therapy. In parallel, our SANTANA-225 study showcases an innovative, first‑in-class approach for patients with ES‑SCLC and MCC. With the SANTANA-225 initial safety readout expected in 2026 and preliminary efficacy in 2027, we remain committed to setting new standards in both research and patient care for diseases with high unmet needs.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000